We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




D‐dimer Levels Predict Ischemic Stroke in Infective Endocarditis

By LabMedica International staff writers
Posted on 17 Feb 2020
Infective endocarditis (IE) is a life‐threatening disease, especially in developing countries. More...
IE may present many extra‐cardiac symptoms or signs, in which neurological complications are the most prominent and severe.

The manifestations of these neurological complications include ischemic stroke, hemorrhagic stroke, mycotic aneurysms, brain abscesses, meningitis, and encephalitis. Ischemic stroke, characterized by the interruption of cerebral blood flow, is a dominant and frequent neurological complication of left‐sided IE, as well as the main stroke type among all stroke cases in IE.

Infectious disease specialists at the Tianjin Medical University General Hospital (Tianjin, China) enrolled in a prospective study, a total of 173 consecutive patients with IE from January 2016 to December 2018. All patients were hospitalized for the first time with a definite diagnosis of IE based on the modified Duke criteria. The primary diagnosis of ischemic stroke was mainly based on clinical neurological symptoms and imaging manifestations on brain magnetic resonance imaging (MRI).

The team performed the measurement of plasma D‐dimer on admission using the VIDAS D‐dimer assay (bioMérieux, Marcy-l'Étoile, France), which has shown comparable sensitivity and specificity. The normal range of plasma D‐dimer is 0‐500 μg/L. Other hematological and biochemical data, such as white blood cell (WBC) count and C‐reactive protein (CRP), were also detected from peripheral blood samples collected on the next morning after admission. In addition, to identify causative organisms, at least three sets of blood cultures were obtained from all patients before the initiation of antibiotic therapy.

The scientists reported that ischemic stroke was observed in 38 (22%) patients during 6‐month follow‐up since definite diagnosis of IE. Patients with ischemic stroke had significantly higher levels of plasma D‐dimer than those of patients without stroke (4,982 versus 2,205 μg/L). Positive results of blood cultures were obtained from 107 (62%) patients. Streptococcus identified in 40 (23%) patients was the most common microorganism, accounting for 37% of all positive blood cultures. The secondary dominant causative agent was Staphylococcus aureus, isolated in 33 (19%) patients and 31% of all positive blood cultures.

In addition, Staphylococcus aureus infection (Hazard Ratio (HR): 1.96), mitral valve vegetation (HR: 1.52), and higher levels of on‐admission plasma D‐dimer (HR: 1.35) were significantly associated with ischemic stroke. Moreover, D‐dimer levels ≥3,393 μg/L served as a strong predictor for ischemic stroke in patients with IE, and the sensitivity and specificity were 78% and 83%, respectively.

The authors concluded that their study revealed that higher levels of on‐admission plasma D‐dimer showed high sensitivity and specificity in the prediction of ischemic stroke, which occurred mostly in the first three months after the diagnosis of IE. On the one hand, as a traditional and inexpensive biomarker, plasma D‐dimer may help clinicians identify high‐risk IE patients for ischemic stroke in a simple and quick way. The study was published on February 3, 2020 in the Journal of Clinical Laboratory Analysis.

Related Links:
Tianjin Medical University General Hospital
bioMérieux



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
New
Gold Member
Serum Indices Control
Acusera Serum Indices Control
New
Microbiology Laboratory Automation Solution
BD Kiestra™ ReadA+BarcodA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image Credit: 123RF

Genetic Testing Program Helps Uncover Inherited Risk in Pediatric Cancer

Inherited cancer risk can affect children, adolescents and young adults, but it may not always be apparent from tumor type or family history alone. Some cancer syndromes require specialized expertise and... Read more

Immunology

view channel
Image: Aptiva utilizes particle-based multi-analyte technology (PMAT) (Photo courtesy of Werfen)

Werfen Expands Automated APS Testing with FDA-Cleared and CE-Marked IgA Reagent

Antiphospholipid syndrome (APS) is an autoimmune disorder associated with thrombosis and pregnancy complications, but its symptoms can overlap with those of other conditions, complicating diagnosis.... Read more

Microbiology

view channel
Image: Each PhAST instrument supports random-access processing of up to four samples simultaneously, delivering a throughput of up to 12 samples per eight-hour shift. (Photo courtesy of PhAST)

FDA Clears Rapid Phenotypic Antimicrobial Susceptibility System for Positive Blood Cultures

Bloodstream infections require prompt treatment, but antimicrobial susceptibility results often lag behind a positive blood culture. Conventional testing can take another 24 to 48 hours after a culture... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image

Collaboration Combines AI Cognitive Assessment and RNA Blood Testing for Earlier Alzheimer’s Detection

Alzheimer’s disease is often identified only after substantial neurodegeneration, partly because current diagnostic pathways are fragmented and difficult to scale. As treatment shifts toward earlier intervention,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.